HELSINKI, August 2, 2022 /PRNewswire/ — Valo Therapeutics Oy (ValoTx), the developer of novel, scalable immunotherapy platforms for cancer and infectious diseases, today announced four appointments to its Scientific Advisory Board (SAB), Professor Paolo A. Asciertodoctor Jeffrey BockmanTeacher Malcolm K. Brennerand teacher Kevin Harrington.
ValoTx CEO, Paul Highhamsaid, “We are delighted to welcome our distinguished new members and experts to the SAB. They bring a wealth of scientific and clinical knowledge that will be of great help in advancing our antigen-coated oncolytic viruses and vaccine vectors as innovative immunotherapy approaches against cancer and infectious diseases. We look forward to working with all of them. »
President of the Scientific Council of ValoTx, Professor Vincenzo Cerullosaid, “It is a great pleasure to have such international scientific and clinical talent with me on Valo’s Scientific Advisory Board. Our innovative solutions for vaccines, immuno-oncology and personalized cancer treatments are life-changing and will overcome some of medicine’s greatest challenges. .”
Teacher Paolo Antonio Ascierto is a global thought leader in the field of melanoma and immunotherapy. He is currently Director of the Department of Melanoma, Cancer Immunotherapy and Developmental Therapeutics at the National Cancer Institute “Pascale” in Napoli, Italy. He is a member of the editorial board, editor and scientific reviewer of leading medical journals and a member of the steering committee of the Society of Melanoma Research (SMR). Dr. Ascierto serves on the board of directors of the Society of ImmunoTherapy of Cancer (SITC) and the Cancer Development Drug Forum (CDDF), and is president of the Fondazione Melanoma Onlus and the Campania Society of ImmunoTherapy of Cancer (SCITO) . He has been a guest speaker at over 400 national and international scientific meetings, courses and workshops. He has chaired as principal investigator over 150 clinical trials and has authored over 600 publications in peer-reviewed journals. His awards and accolades are numerous and include the GEF Health Award in 2022. He has received funding from POR FESR and ERA-NET, among others.
Doctor Jeffrey Bockman received a BA from University of California San Diegoa master’s degree in English/creative writing from New York Universityand a doctorate in medical microbiology from the University of California at Berkeley. He is Executive Vice President, Head of Oncology at Lumanity BioConsulting, and was Adjunct Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel laureates: Dr. Sidney Altmanon ribozymes, and Dr. Stanley Prusiner, on prions. He brings to the SAB a broad commercial and strategic perspective on the pharmaceutical and biotechnology industries, including leading the commercial development of oligonucleotide therapies for viral diseases and cancer at Innovir Laboratories. He is a frequent speaker at industry events such as BIO on the intersection of scientific, clinical and strategic issues affecting biotechnology oncology drug development. Jeff is a member of AACR, ASCO, ASH, ASGCT, SITC and NYAS. He is a mentor for the NCI Innovation Conference, a judge for the Citeline Awards, a member of the advisory panel of Skipper Bio Med and a member of the clinical advisory board of ImmunOS (Zürich) and the scientific council of hC Bioscience (Cambridge, MA).
Professor Malcolm K. Brenner is an award-winning physician-scientist who pioneered the therapeutic use in cancer of immunological T-cell approaches and genetic engineering strategies. He is the founding director of the Center for Cellular and Gene Therapy, Baylor College of Medicine (BCM), Houston Methodist Hospital and Texas Children’s Hospital. He was editor of Molecular Therapy and past president of the American Society for Gene and Cell Therapy and the International Society for Cell Therapy. Dr. Brenner earned his medical degrees and doctorate at the University University of Cambridge, England. Dr. Brenner’s work has been funded by the NIH-NCI, the Leukemia and Lymphoma Society, the Cancer Prevention and Research Institute of Texas, and several charitable foundations. He participated in the creation of several companies, such as Allovir, Marker Therapeutics and Tessa Therapeutics.
Teacher Kevin Harrington medical degree from the University of London and received his doctorate from Imperial College, London. He is a Fellow of the Royal College of Physicians and the Royal College of Radiologists. He completed postdoctoral training in clinical oncology (Royal College of Radiologists Rohan Williams Medal) and postdoctoral research with Professor by Richard Ville Mayo Clinic Molecular Medicine Program laboratory. He was later appointed to a group leader position at the Institute for Cancer Research (ICR), London and an Honorary Consultant Oncologist position at the Royal Marsden Hospital (RMH). He is Head of the Radiotherapy and Imaging Division at ICR and Director of the CRUK ICR/RMH RadNet Center of Excellence. He has led phase I, II and III trials of oncolytic virotherapies, immunotherapy and radio-drug combinations. He brings to SAB a longstanding focus on gene therapy and viral gene therapy as means to selectively destroy cancer cells and activate anti-tumor immune responses. His laboratory research focuses on the use of biologically targeted agents, in combination with treatments such as radiation therapy and chemotherapy, to selectively target cancer cells, particularly in head and neck cancer and in melanoma. .
Valo Therapeutics Oy (helsinki) is an immunotherapy company that develops innovative immunotherapy approaches against cancer and infectious diseases. ValoTx’s main platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed by the laboratory of Professor Vincenzo Cerullo to University of Helsinki. It transforms oncolytic adenoviruses into targeted tissue-specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV and PeptiVAX, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to oncolytic enveloped viruses in the treatment of multiple forms of cancer, while PeptiVAX is a program to develop a new adaptable anti-infective vaccination platform. PeptiVAX’s lead project is a pan-coronavirus T-cell vaccine. The Company’s PeptiCHIP technology enables rapid and accurate identification of tumor antigens. A film explaining the PeptiCRAd technology is available here.
SOURCE Valo Therapeutic